GTC Biotherapeutics (GTCB) Enters Follow-On Biologic Founder Development Collaboration with AgResearch  
2/26/2009 9:46:04 AM

FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) has entered into a collaboration agreement with AgResearch Limited of New Zealand to develop transgenic founder animals to produce two follow-on biologic, also referred to as biosimilar, monoclonal antibodies. The establishment of a production capability outside of the United States is an important step in GTC’s long term biosimilar strategy. This approach will enable earlier sales of the products in territories such as Europe where the relevant patents expire before the associated patents in the United States.